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Background: The United States Preventive Services Task Force (USPSTF) recommends screening adults for
depression in primary care settings when staff-assisted depression management programs are available. This
recommendation, however, is based on evidence from depression management programs conducted with patients
already identified as depressed, even though screening is intended to identify depressed patients not already
recognized or treated. The objective of this systematic review was to evaluate whether there is evidence from
randomized controlled trials (RCTs) that depression screening benefits patients in primary care, using an explicit
definition of screening.
Methods: We re-evaluated RCTs included in the 2009 USPSTF evidence review on depression screening, including
only trials that compared depression outcomes between screened and non-screened patients and met the
following three criteria: determined patient eligibility and randomized prior to screening; excluded patients already
diagnosed with a recent episode of depression or already being treated for depression; and provided the same
level of depression treatment services to patients identified as depressed in the screening and non-screening trial
arms. We also reviewed studies included in a recent Cochrane systematic review, but not the USPSTF review;
conducted a focused search to update the USPSTF review; and reviewed trial registries.
Results: Of the nine RCTs included in the USPSTF review, four fulfilled none of three criteria for a test of depression
screening, four fulfilled one of three criteria, and one fulfilled two of three criteria. There were two additional RCTs
included only in the Cochrane review, and each fulfilled one of three criteria. No eligible RCTs were found via the
updated review.
Conclusions: The USPSTF recommendation to screen adults for depression in primary care settings when staff-assisted
depression management programs are available is not supported by evidence from any RCTs that are
directly relevant to the recommendation. The USPSTF should re-evaluate this recommendation.
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Screening for depression in primary care settings is con-
troversial [1-3]. Prior to 2002, no major guidelines recom-
mended depression screening. Then, in 2002, the United
States Preventive Services Task Force (USPSTF) recom-
mended routine depression screening when staff-assisted
depression care programs are in place to ensure ac-
curate diagnosis and effective treatment and follow-up
[4]. In 2009, the USPSTF reiterated this recommenda-
tion, based on evidence from nine randomized controlled
trials (RCTs) [5,6].
By contrast, a 2008 Cochrane review [7,8] reported that
the effect of depression screening on depressive symptoms
in five RCTs was virtually zero (standardized mean diffe-
rence = -0.02, 95% confidence interval -0.25 to 0.20) [7].
Consistent with this, in 2010, the UK National Institute
for Health and Care Excellence recommended that clini-
cians be alert to possible depression, but not screen [9].
In 2013, the Canadian Task Force on Preventive Health
Care similarly recommended against routine depression
screening [10].
Existing systematic reviews on depression screening
have been criticized for not defining the characteristics of
depression screening trials [11,12]. Depression screening
involves the use of depression symptom questionnaires to
identify patients who may have depression but have not
sought treatment and have not otherwise been recognized
as depressed by healthcare providers. For screening to
benefit patients, patients must agree to be screened, the
screening test must accurately identify a significant number
of previously unrecognized patients, and clinicians must
engage these patients in treatment and obtain sufficiently
positive results to justify costs and potential harms [3].
A trial of depression screening must be able to sepa-
rate the effect of screening from the effect of providing
additional treatment resources not otherwise available.
In addition to screening, depression symptom question-
naires may be used for tracking symptom severity or de-
tecting relapse among patients with already-recognized
depression. However, in a trial, only patients not already
under care for depression prior to the trial should be in-
cluded in assessing the effect of screening, since screen-
ing is done to identify previously unrecognized cases.
Thus, for a trial to test the effects of depression screen-
ing on depression outcomes, at least three key criteria
must be fulfilled. The trial must:
1. determine patient eligibility and randomize patients
prior to screening;
2. exclude patients already diagnosed with a recent
episode of depression or being treated for depression
at the time of trial enrollment;
3. provide similar depression management options to
patients with depression in the screening arm ofthe trial and patients in the non-screening arm
identified as depressed via other mechanisms,
such as patient report or unaided physician
diagnosis.
The 2009 USPSTF systematic review [5,6] did not ex-
plicitly define characteristics of a screening trial. The
2008 Cochrane review [7,8] excluded trials where de-
pression care was substantially enhanced for patients in
the intervention group only, but did not require ran-
domization prior to screening or address the inclusion
of already-treated patients.
The objective of the present systematic review was
to determine whether the USPSTF depression screen-
ing guideline is supported by evidence that depression
screening improves depression outcomes in primary
care. To do this, we re-evaluated the nine RCTs included
in the 2009 USPSTF systematic review on depression
screening [5,6] to determine if they fulfilled the three
key criteria necessary for a test of depression screening.
In addition, we reviewed trials included in the 2008
Cochrane review [7,8] and conducted a focused search
to determine if any depression screening trials have
been conducted since those reviews.
Methods
Methods for this systematic review were registered in
the PROSPERO prospective register of systematic re-
views (#CRD42013004276).
Identification of eligible RCTs from the 2009 USPSTF and
Cochrane systematic reviews
We evaluated nine RCTs from the USPSTF 2009 review
and two additional RCTs that were included in one or
both published versions of a Cochrane review [7,8] but
not the USPSTF review. Eligible RCTs had to use a de-
pression screening tool with a defined cut-off score to
make decisions regarding further assessment or treat-
ment of depression. In addition, patient eligibility and
randomization had to occur prior to administering the
screening test; patients with a recent diagnosis of de-
pression and patients being treated for depression close
to the time of trial enrollment had to have been ex-
cluded from the trial; and similar depression manage-
ment resources had to have been available to patients
identified as depressed in both trial arms. We included
RCTs that compared depression symptom outcomes or,
if not available, number of cases post-screening, but not
RCTs that only reported rates of depression recognition
or treatment. This is because recommendations for scree-
ning should be based on evidence of improved outcomes.
Increased treatment without improved depression out-
comes would expose patients to costs and potential harms
but not benefit [3].
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publications of RCTs from the USPSTF and Cochrane
reviews with any disagreements resolved by consensus.
Updated search
We searched for RCTs from any country that met eligi-
bility criteria. The focused database search was designed
based on a surveillance technique found to be the most
effective method for finding new evidence to update
systematic reviews in a comparison of several different
methods [13]. It involved using a combination of two
separate search strategies. The first was a subject search
in the MEDLINE database using relevant Medical Sub-
ject Headings and text words. The second search was a
‘related citations’ search in PubMed based on the three
most recent and three largest trials included in either
the USPSTF or Cochrane reviews, only including studies
that were described in the original publications as re-
lated to screening. Both searches were limited to RCTs
by using a validated methodological hedge. The search
was peer-reviewed prior to implementation on 24 April
2013, using the Ovid SP interface for MEDLINE (search
1) and the National Library of Medicine interface,
PubMed (search 2). See Additional file 1.
We also searched the ClinicalTrials.gov trial registry
(‘depression AND screen*’ in any field, where * retrieves
terms with zero to more characters) and the World
Health Organization International Clinical Trials Regis-
try Platform (‘depression AND screen*’ in the ‘title’ field)
from inception to 30 April 2013. The World Health Or-
ganization registry platform is a central database that pro-
vides access to many different clinical trial registries from
around the world.
The updated review was similarly done independently
by two investigators.
Data presentation and synthesis
Since we did not identify any trials that met all three cri-
teria necessary for tests of depression screening, synthe-
sis of outcome data on the effect of depression screening
was not possible. Instead, we reported the results of our
evaluation to determine if RCTs from the USPSTF and
Cochrane reviews or the updated search fulfilled the
three criteria. We did not conduct an assessment of trial
quality or risk of bias because no trials met criteria to be
considered a test of depression screening. Two investiga-
tors independently extracted data with any disagreement
resolved by consensus.
Results
Re-assessment of randomized controlled trials from 2009
USPSTF and Cochrane systematic reviews
As shown in Table 1, there were five RCTs [14-18] in-
cluded in only the USPSTF review, four [19-22] includedin both the USPSTF and Cochrane reviews, and two
[23,24] included in at least one version of the Cochrane
review, as well as a 2002 version of the USPSTF review
[25] but not the 2009 USPSTF review. Of the 11 RCTs
included in either the 2009 USPSTF or Cochrane re-
views, one [20] fulfilled two of the three key criteria for
a depression screening trial, six [16,17,21-24] fulfilled
one, and four [14,15,18,19] did not fulfill any. Of the 11
RCTs, only two [20,21] determined trial eligibility and
randomized prior to screening; only two [16,17] exclu-
ded already diagnosed and treated patients; and only four
[20,22-24] provided similar depression management op-
tions to patients in both trial arms.
Of the five RCTs [14-18] that were included in the
USPSTF review but not the Cochrane review, four [14-17]
were trials of complex depression care quality improve-
ment programs and required a positive score on a dep-
ression screening tool plus a diagnosis of depression for
enrolment. The other RCT [18], also a complex manage-
ment intervention, was excluded from the Cochrane
review because it was not specific to depression. For
eligibility, elderly patients were required to have four
of ten problems indicative of a potentially poor gen-
eral prognosis, but not necessarily depression.
Results from the updated search
The trial registration search included 405 unique trial
registrations, but none described RCTs that met eligibi-
lity criteria. The database search identified 347 unique
citations, of which 342 were excluded after title and ab-
stract review and five after full-text review (Figure 1). Of
the five studies that underwent full-text review, two stu-
dies were clearly not relevant, and three RCTs [30-32]
were similar in design to trials included in the USPSTF
or Cochrane reviews and met at least one criterion (see
Table 1). Of these three RCTs, one [30] met one, and
two [31,32] met two of the three criteria.
Randomized controlled trials that randomized patients
prior to screening
Among RCTs included in the USPSTF or Cochrane
reviews or identified in the updated search, only four
[20,21,31,32] determined eligibility and randomized pa-
tients prior to screening. Among those, one [31] pro-
vided enhanced depression care to only patients in the
screening arm, which did not allow an assessment of the
effect of screening. Another [21] randomized patients to
physician notification of positive screens versus usual
care. Intervention arm patients with positive depression
screens were offered six weekly depression education
sessions, although only 12% of eligible patients attended.
Outcome data were analyzed from only the 14% of pa-
tients in the trial with positive screening scores at baseline,
including patients on antidepressants pre-trial. There were

































Both 175 Patients with CES-D≥ 16 and
HAMD≥ 15 eligible and randomized
to enhanced depression care versus
usual care.
No 21% of enrolled patients already












116 Patients with BDI ≥14 eligible and
randomized to have their BDI scores
and diagnostic interpretation disclosed
to their physician or not disclosed.
No Patients excluded if their
physicians believed they were
currently depressed, but already
diagnosed and already treated
patients not necessarily excluded.b







454d Patients with GHQ-12 ≥2 eligible and
randomized to have their GHQ-12
scores placed in their physician’s notes
or not disclosed.
No Existing depression diagnosis or
treatment not in exclusion criteria.
No information on depression
diagnosis or treatment at time
of enrollment provided.





Both 969e Patients randomized to screening with
single mood question, with the CES-D,
or to usual care. Depression outcomes
only assessed for 97 patients with major
depression at baseline and a sample of
119 other patients.
Yese Only 11 of 41 diagnoses of
depression post-screening were
new diagnoses (27%). Patients
classified as new diagnoses if
no evidence of diagnosis in
chart and patient reported that
not diagnosed or treated in
last 2 years.f





USPSTF 1356 Patients with probable depressive
disorder eligible and randomized to
enhanced depression care versus usual
care.
No In 6 months prior to trial, 48%
of patients discussed emotional
issues at medical visit; 29% had
specialty mental health visit; 44%






Control arm: usual care.
Whooley 2000,
US [21]
Both 2346g Patients randomized to screening with
GDS and seven educational sessions
versus usual care. Only 331 patients
with GDS ≥6 at baseline included in
depression outcome analysis.
Yesg In 12 months prior to trial, 20%







plus one booster session.
No



















Table 1 Characteristics of randomized controlled trials in 2009 United States Preventive Services Task Force and Cochrane systematic reviews (Continued)
Rost 2001,
US [15,28,29]
USPSTF 479 Patients with five or more symptoms
of current MDD eligible. Practices
randomized to enhanced depression
care versus usual care.
No In 6 months prior to trial, 44%
of patients were prescribed
antidepressant medication or






Control arm: usual care.
Jarjoura 2004,
US [16]
USPSTF 61 Patients positive for depression on
PRIME-MD eligible and randomized
to nurse-supported depression
management and referral program
versus usual care.
No Patients receiving intervention
for mental health problems or









Control arm: usual care.
Bergus 2005,
US [22]
Both 51 Patients with low mood or anhedonia
in last two weeks based on PHQ-9
eligible and randomized to have
their PHQ-9 scores disclosed to their
physician or not disclosed.
No 38% of enrolled patients on
medication for depression or
anxiety at time of enrollment








USPSTF 145 Patients with GDS ≥5 and positive for
depression on PRIME-MD eligible and
randomized to enhanced depression
care versus usual care.
No Patients using antidepressants






Control arm: usual care.
Rubenstein
2007, US [18]
USPSTF 792 Patients were randomized to practices
in a Veterans Administration healthcare
system that provided enhanced geriatric
care versus usual care. Patients positive
on ≥4 of 10 GPSS items related to
falls/balance, urinary incontinence,
depression, memory loss, pain, weight
loss, polypharmacy and general health
were eligible.i
Nog Existing depression diagnosis
or treatment not in exclusion
criteria. No information on
depression diagnosis or






Control arm: usual care.
Yeung 2010,
US [30]
Updated Search 100 Patients with confirmed MDD
randomized to enhanced depression
care versus usual care.
No Patients already receiving






Control arm: usual care.
Yawn 2012,
US [31]
Updated Search 2343j Primary care practices were
randomized to a complex depression
care intervention, including screening
with EPSD and PHQ-9, versus usual
care. Women 5 to 12 weeks postpartum
were eligible. Only 408 patients with
positive depression screen at baseline
included in depression outcome
analysis.
Yesj Existing depression diagnosis
or treatment not in exclusion
criteria. No information on
depression diagnosis or

























Table 1 Characteristics of randomized controlled trials in 2009 United States Preventive Services Task Force and Cochrane systematic reviews (Continued)
Romera 2013,
Spain [32]
Updated Search 3737 Primary care physician practices were
randomized to training on screening
with 2 questions and usual depression
care versus usual care. After 6 months,
3737 patients randomly selected for
depression assessment.
Yes Existing depression diagnosis
or treatment not in exclusion
criteria. No information on
depression diagnosis or
treatment at time of
enrollment provided.
No Both groups received
usual care.
Yes
aDowrick et al. trial was included in the 2002 USPSTF review, but excluded from the 2009 USPSTF review with note, ‘Does not report included outcomes’. The exclusion note referenced only one of the published
trial reports [23], which did not provide depression outcomes, but did not cite another published report [26] that did provide depression outcomes. bBased on published articles and clarification provided by
corresponding author. cLewis et al. trial was included in the 2002 USPSTF review, but excluded from the 2009 USPSTF review with note, ‘Missing both depression-specific screener and depression-specific outcomes’.
The GHQ-12 appears to have been considered a depression screening and depression outcome in the 2002 review, but not in the 2009 review. dThe trial included three arms with 227 in each arm. One arm, however,
included screening with a short questionnaire and a 15- to 45-minute computerized diagnostic interview for depression. Consistent with the Cochrane review [7] and because the diagnostic interview is not screening,
we evaluated only two trial arms. eEligibility was determined and randomization occurred pre-screening. However, only 216 of 969 patients randomized (23%) were assessed for depression outcomes. fBased on
published article and clarification provided by corresponding author. gEligibility was determined and randomization occurred pre-screening. However, only 331 of 2,346 patients randomized (14%) were include in
depression outcome analysis. hPatients receiving other forms of depression treatment were not excluded, but the number of patients receiving other forms of treatment was not reported. iScreening was done based
on many problems faced by elderly patients. Only 46% of patients in the trial screened positive on a single item related to depression. jEligibility was determined and randomization occurred pre-screening. However,
only 408 of 2,343 patients randomized (17%) were assessed for depression outcomes. BDI, Beck Depression Inventory; CES-D, Center for Epidemiological Studies Depression Scale; GDS, Geriatric Depression Scale;
GHQ-12, General Health Questionnaire, 12-item version; GPSS, Geriatric Postal Screening Survey; HAMD, 21-item Hamilton Depression Rating Scale; MDD, major depressive disorder; PHQ-9; 9-item Patient Health



















347 Unique titles/abstracts 
identified and screened 
for potential eligibility
342 Titles/abstracts excluded: 
No original data or case report (21)
Not adult primary care (153)
Not an RCT of depression screening (168)
5 Articles selected for 
full-text review
5 Articles excluded:
Not adult primary care (1)
Not an RCT of depression screening (4)
0 Depression screening 
trials included in 
systematic review
Figure 1 PRISMA flow diagram of study selection process for updated search. RCT, randomized controlled trial.
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sion symptoms between groups (-2.4 versus -2.1 points on
Geriatric Depression Scale, P = 0.50).
Two trials [20,32] met two of the three criteria, but in-
cluded already diagnosed or treated patients. One [20]
analyzed data from only 23% of patients randomized, in-
cluding patients determined to have major depression at
baseline plus a small sample of patients without major
depression at baseline. Only 27% of depression diagnoses
post-screening were new diagnoses, and the mean re-
duction in the number of depressive symptoms did not
differ between the two groups (1.6 versus 1.5 symptoms,
P = 0.21). The other [32] was a cluster RCT in which pri-
mary care practices were randomized to screen versus
provide usual care to patients at high risk of depression
due to a history of depression, unexplained somatic symp-
toms, psychological comorbidities, drug abuse or chronic
pain. The number of patients already treated pre-trial was
not reported. Rates of depression post-screening were
similar in the screening (15.0%) and usual care (15.8%)
trial arms.
Discussion
The main finding of this systematic review was that
no RCTs have compared depression outcomes be-
tween patients randomized to be screened versus not
screened for depression in trials that met the neces-
sary criteria: determined eligibility and randomizedpatients prior to screening; excluded patients already
known to have depression or already being treated
for depression; and provided similar depression man-
agement options to patients identified as depressed
via screening or via other methods in the compari-
son group.
The 2009 USPSTF recommendation to screen when
collaborative care depression management programs are
available was based primarily on the results of three trials
[14,15,18]. Two of these trials [14,15] compared complex
collaborative care depression management programs to
usual care among patients required to have depression to
enroll in the trials. In one of the trials, 44% of enrolled pa-
tients were described as receiving appropriate mental
health care in the 6 months prior to trial enrollment [14].
In the other, 44% of enrolled patients were prescribed
antidepressant medication or had a specialty mental
health care visit in the 6 months prior to enrolling in
the trial [15]. The third trial tested whether telephone
case management improved a series of geriatric out-
comes (depression, cognitive impairment, urinary in-
continence, falls, functional impairment) among elderly
patients determined to be at risk for poor health out-
comes prior to trial enrollment, most of whom did not
report symptoms of depression [18]. None of these trials
met any of the three criteria used in the present system-
atic review to characterize trials of depression screening
programs.
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ommendation provided evidence that collaborative care
programs improve outcomes compared to usual care for
patients already identified as depressed. They did not,
however, address the question of whether screening im-
proves outcomes for patients who would not otherwise
be identified as depressed in the context of these pro-
grams. To address this question, RCTs are needed that
randomize primary care practices to screen patients for
depression versus not screening them. All patients in
either trial arm who are identified as depressed via scree-
ning or other mechanisms, such as unaided clinician rec-
ognition or patient report, should be provided with the
same depression care to determine whether screening is
linked to improved depression outcomes in the context of
depression care of similar quality (Figure 2).
Without such evidence, the USPSTF should consider
several factors that suggest that depression screening,
even in the context of collaborative depression care, may
not be straightforward or effective, and may, in fact, ex-
pose some patients to avoidable risk. These factors have
been discussed in detail elsewhere [3], but include the
already high rate of antidepressant use in primary care
settings [33,34]; the likely overestimation in the research
literature of the accuracy of depression screening tools
for identifying previously unrecognized cases of depres-
sion [35]; and the limited effectiveness of antidepressant
medication among patients with only mild symptoms of
depression [36-41], including patients without obvious
depression who would likely be identified via screening.Primary care practi
Practices allocated to screen for depression in 
addition to usual depression identification 
procedures (clinician recognition, patient report)
Patients identified as depressed via screening, 
clinician recognition, or patient report provided 
depression care*
Exclude from outcome analyses patients already 
receiving depression care prior to trial
Figure 2 Diagram of trial to test depression screening in the contextAlthough it is not clear that depression screening
would improve depression outcomes, it would harm
some patients [42]. Most patients treated for depression
in primary care are treated with antidepressants [43],
and common side effects include diarrhea, dizziness, dry
mouth, fatigue, headache, nausea, sexual dysfunction, ex-
cessive sweating, tremors and weight gain [44]. Less
common but potentially more serious adverse effects,
particularly for patients in primary care with heart dis-
ease, may include increased risk of bleeding and un-
wanted effects on blood pressure and heart rate [45-49],
as well as drug-drug interactions with cardiac medica-
tions [50,51]. For patients with generally low levels of
depression, who are most likely to be newly identified
through screening, the side effect burden and potential
risk profile of antidepressants need to be carefully con-
sidered, particularly given that screening has not been
shown to reduce symptoms of depression.
Screening would also consume scarce healthcare re-
sources [52,53] that will not then be available for other
activities, such as providing treatment to the large num-
ber of patients already diagnosed with depression but re-
ceiving poor-quality care. Canadian healthcare costs are
generally lower than those in the US. Nonetheless, a re-
cent population-based study from the province of Quebec
found that overall healthcare costs were approximately
$2,000 (CAD) higher for patients prescribed antidepres-
sants, with a large proportion of increased costs attributed
to patients without a recent history of depression or an-
xiety [54]. The cost of treatment, however, is only part ofces randomized
Patients identified as depressed via clinician 
recognition or patient report provided depression 
care*
Practices allocated to usual depression identification 
procedures (clinician recognition, patient report) 
Exclude from outcome analyses patients already 
receiving depression care prior to trial
of collaborative depression care.
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symptom questionnaires, the cost of depression screening
would include follow-up assessments to determine which
patients are true positive screens and which are false posi-
tives; consultations with patients who are identified as
having depression to determine management options and,
if treatment is advised, the best treatment option; as
well as treatment and follow-up services. The USPSTF
guideline does not specify how often patients should be
screened, and we do not know of any studies that have ex-
amined cumulative false positive rates from repeat scree-
nings, but this is an important factor that needs to be
considered.
Recommendations have been made for depression
screening of special patient populations, including post-
partum women [55] and patients with heart disease
[56]. However, these recommendations are controver-
sial [57,58] and not supported by evidence of benefit
from RCTs [59-62]. In the UK, depression screening
in primary care of patients with heart disease and diabetes
was incentivized from 2006 to 2013. An analysis of more
than a million patient records from Scottish primary care
practices, however, found that almost 1,000 screens were
necessary for a new depression diagnosis and almost 700
for a new antidepressant prescription [63]. In the US, at
least 10 states have legislation encouraging or requiring
postpartum depression screening [64]. Although no de-
pression outcomes have been reported, a study of the first
of these programs to be initiated, the New Jersey Postpar-
tum Wellness Initiative, which has required postpartum
depression screening since 2006, did not find any increase
in depression treatment or follow-up care following imple-
mentation [64].
The only RCT in the present review that screened
high-risk patients [32] did not find that screening reduced
the presence of depression, although it is not known what
proportion of patients in the trial were receiving treatment
for depression pre-trial. One prospective cohort study
from the Netherlands [65] documented the results of a
program designed to screen and provide collaborative de-
pression care for primary care patients with a history of
mental health problems, unexplained somatic complaints,
or a high level of service utilization. In that study, 1,687
patients were sent a screening questionnaire and letter
from their general practitioner: 780 returned the screening
questionnaire and 226 screened positive, but only 17 pa-
tients were newly diagnosed with depression and attended
even one session of the offered treatment. Depression out-
comes were not reported.
The present systematic review is a focused update of
existing systematic reviews and did not include a com-
plete search as in earlier reviews. Therefore, it is possible
that we could have missed eligible trials. However, the up-
dating method that we used has been validated as highlysensitive [16], and the likelihood that we have missed eli-
gible studies that would have changed results appears to
be very low.
Conclusions
We did not find any directly relevant evidence from
RCTs to support the USPSTF recommendation to screen
patients for depression in primary care when staff-
assisted, collaborative depression care programs are in
place. This result is consistent with recent guidelines
from the UK [9] and Canada [10] that concluded that
routine depression screening is not supported by exis-
ting evidence. Our results differ from those of a 2008
Cochrane review [7,8], which reported that depression
screening is not effective based on evidence from five
trials by clarifying that there have not been any well-
designed trials to directly address the question of whe-
ther depression screening may be effective, particularly
in the context of collaborative care. RCTs of depression
screening that are designed to directly assess whether
screening of previously unidentified patients will reduce
rates of depression are needed.
Over-diagnosis and over-treatment of depression are
common in community and primary care settings in the
US [66-68], and there is a real risk that depression scree-
ning could exacerbate this problem without contributing
to better mental health. We hope that the USPSTF will
re-evaluate evidence on depression screening, applying
the three basic criteria that we have used in this review.
Before screening for depression is recommended, there
should be evidence of improved depression outcomes
from well-conducted depression RCTs that are directly
relevant to the question of screening.
Although our findings show that there is not enough
evidence to recommend that healthcare practitioners use
screening to attempt to identify patients who may have
depression, depression is a disabling condition with a
major impact on quality of life. Thus, clinicians should
be aware of signs that depression may be present, such
as low mood, loss of interest in activities, insomnia and
fatigue [10]. Healthcare practitioners should be particu-
larly vigilant among patients who may be at high risk of
depression, including patients with a chronic medical
condition, a past history of depression, a pattern of un-
explained somatic symptoms and frequent use of me-
dical services, or substance abuse [9,10,32,65].
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